Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norfolk, VA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Virginia Beach, VA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Williamsburg, VA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Williamsburg, VA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Winchester, VA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Winchester, VA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Woodbridge, VA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Woodbridge, VA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Vancouver, WA
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
mi
from
Hong Kong,
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
mi
from
Hong Kong,
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Community Awareness Resources and Education - Project 1
Reducing Cervical Cancer in Appalachia
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Community Awareness Resources and Education - Project 1
Reducing Cervical Cancer in Appalachia
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Aurora, CO
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Shreveport, LA
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Rochester, MN
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tupelo, MS
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Newark, NJ
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hershey, PA
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Pittsburgh, PA
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Muenchen,
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Muenchen,
Click here to add this to my saved trials
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
Androgen Receptor (AR) Activity in Castration-Resistant Prostate Cancer (CRPC) and Response to Ketoconazole
Status: Enrolling
Updated:  12/31/1969
Alliance for Clinical Trials in Oncology
mi
from
Boston, MA
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
Androgen Receptor (AR) Activity in Castration-Resistant Prostate Cancer (CRPC) and Response to Ketoconazole
Status: Enrolling
Updated: 12/31/1969
Alliance for Clinical Trials in Oncology
mi
from
Boston, MA
Click here to add this to my saved trials
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Essentia Health SMDC Cancer Center
mi
from
Duluth, MN
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Essentia Health SMDC Cancer Center
mi
from
Duluth, MN
Click here to add this to my saved trials
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Status: Enrolling
Updated:  12/31/1969
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Status: Enrolling
Updated: 12/31/1969
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Status: Enrolling
Updated:  12/31/1969
University of Maryland at Baltimore/MPRC
mi
from
Catonsville, MD
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Status: Enrolling
Updated: 12/31/1969
University of Maryland at Baltimore/MPRC
mi
from
Catonsville, MD
Click here to add this to my saved trials
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Lousiana State University Health Sciences Ctr - New Orleans
mi
from
New Orleans, LA
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Lousiana State University Health Sciences Ctr - New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Family Communication of Hereditary Cancer Risk Among African Americans
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Family Communication of Hereditary Cancer Risk Among African Americans
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Cancer Center
mi
from
Tucson, AZ
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer
Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer "Can we Kick Down Ki-67, Punch Out Insulin Resistance, and Increase Survival?"
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer
Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer "Can we Kick Down Ki-67, Punch Out Insulin Resistance, and Increase Survival?"
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer
Evaluation of a Novel Molecular NSCLC Classification System
Status: Enrolling
Updated:  12/31/1969
Alliance for Clinical Trials in Oncology
mi
from
Boston, MA
Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer
Evaluation of a Novel Molecular NSCLC Classification System
Status: Enrolling
Updated: 12/31/1969
Alliance for Clinical Trials in Oncology
mi
from
Boston, MA
Click here to add this to my saved trials
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
Adapting Smoking Cessation Interventions for the Outpatient Oncology Setting
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
Adapting Smoking Cessation Interventions for the Outpatient Oncology Setting
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
The Treatment of Stage I and II Breast Cancer With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Radiotherapy
The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Definitive Irradiation
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Treatment of Stage I and II Breast Cancer With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Radiotherapy
The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Definitive Irradiation
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute - St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute - St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
John Wayne Cancer Institute at St. John's Health Center
mi
from
Santa Monica, CA
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
John Wayne Cancer Institute at St. John's Health Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
NorthShore University Health System
mi
from
Chicago, IL
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
NorthShore University Health System
mi
from
Chicago, IL
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
A Phase I Study of Preoperative Chemoradiation With Oxaliplatin, 5-Fluorouracil, Erlotinib and Radiation Followed by Resection and Consolidative Erlotinib for Patients With Locally Advanced Cancer of the Esophagus and Gastroesophageal Junction
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
A Phase I Study of Preoperative Chemoradiation With Oxaliplatin, 5-Fluorouracil, Erlotinib and Radiation Followed by Resection and Consolidative Erlotinib for Patients With Locally Advanced Cancer of the Esophagus and Gastroesophageal Junction
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ohio Patient Navigator Research Program
Ohio Patient Navigation Research Program
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Ohio Patient Navigator Research Program
Ohio Patient Navigation Research Program
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
Pulmonary Rehabilitation Before Lung Cancer Resection
Pulmonary Rehabilitation Before Lung Cancer Resection
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Safety Study Assessing the Effects of Receiving Genome Sequencing Results
Personal Genomics: A Safety Study Assessing the Effects of Receiving Genome Sequencing Results
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study Assessing the Effects of Receiving Genome Sequencing Results
Personal Genomics: A Safety Study Assessing the Effects of Receiving Genome Sequencing Results
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients
Use of Nutritional Supplements and CAM (Complementary and Alternative Medicine) by Prostate and Breast Cancer Patients Undergoing Radiotherapy
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients
Use of Nutritional Supplements and CAM (Complementary and Alternative Medicine) by Prostate and Breast Cancer Patients Undergoing Radiotherapy
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials